Weekly Glance for July 30th

What's new in optometry, week by week.

This week is brought to you by


Roclatan may be on your sample shelf soon.

What is Roclatan?
It's a drop used once daily to lower IOP and it's a combo of two drugs, latanoprost and Rhopressa. You've heard a lot about Rhopressa recently because it just received FDA approval at the end of 2017.

Remind me, how does Rhopressa work?
The main buzz word you will hear is that it's a ROCK inhibitor. Rock inhibitors increase outflow through the trabecular meshwork by inhibiting Rho Kinase (ROCK). Rhopressa is also presumed to work via two other mechanisms:
-- It reduces fluid production in the eye by inhibiting the norepinephrine transporter (NET Inhibitor).
-- It lowers episcleral venous pressure.

Latanoprost is a prostaglandin analog (which works by increasing uveoscleral outflow) and prostaglandin analogs remain the first line treatment for most glaucoma patients.

So Rhopressa + latanoprost = Roclatan could be a big deal. The clinical studies have shown Roclatan to be superior at lowering IOP than Rhopressa or latanoprost alone (study highlights here).

When might this be approved?
The FDA is reviewing the new drug application but the review is expected to be completed in March 2019.



Can turmeric help prevent glaucoma?

According to a new study, yes.

First, what is turmeric?
It's a plant from the ginger family recognized for it's bright yellow/orange color. It's commonly used in a dry powder form and many types of curry use turmeric as a key ingredient to add flavor.

What is so great about turmeric?
Its active ingredient, curcumin. Curcumin has antioxidant properties and has been shown to protect retinal ganglion cells when administered orally. 

Why don't we just take it orally?
The problem with oral administration is that curcumin has poor solubility and therefore doesn't efficiently get absorbed into the blood stream. A person would need to take up to 24 pills a day to get the benefits which leads to GI side effects.

What did the study find?
A new study designed a drop containing curcumin within a nanocarrier. The nanocarrier allows for administration of high doses of curcumin as well as increased solubility. Using the drop twice a day for three weeks in rat models with glaucoma showed a reduction in retinal ganglion cell loss compared with the controls. (via)



The week in numbers:

The number of clinics in the US offering patients non-FDA approved “cell therapy” for ocular conditions. (via)

The number of hours per year spent in front of a computer screen for the average office worker. (via)

The prevalence of amblyopia in kids age 6 months to 6 years according to Prevent Blindness. Related, August is Children’s Eye Health and Safety Month.

The number of genetic factors identified for myopia.

1 Billion
The number of active users on Instagram. I'm one of them and if you like cool eye pics, follow me there!

This is sponsored content by Vision Expo!

Need to get some CE out of the way?

Head to the desert! Vision Expo West has great education, a ton of networking opportunities, thousands of eyewear brands, and the latest medical technologies. Save $150 and register here for free!
Great work this morning!
I'm off next Monday but I'll see you back here on the 13th!
Have a great week!

Jackie Garlich
Editor & Founder // 20/20 Glance

Enjoy this email? Tell your friends to sign up here!
Have news or a comment to share?
Copyright © 2018 2020glance, All rights reserved.

Email Me // About // Update Profile // Unsubscribe